Maintenance tegafur-uracil versus observation following an adjuvant oxaliplatin-based regimen in patients with stage III colon cancer after radical resection: Study protocol for a randomized controlled trial

Yung Sung Yeh, Hsiang Lin Tsai, Ching Wen Huang, Po Li Wei, Yung Chuan Sung, Hsiu Chih Tang, Jaw Yuan Wang

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: We conducted a prospective randomized study of an adjuvant oxaliplatin-based regimen plus orally administered tegafur-uracil in patients with stage III colon cancer after radical resection to evaluate the feasibility of this drug combination in cancer clinical outcomes, acute toxicity, disease-free survival (DFS), and overall survival (OS) in Taiwan. Methods/design: This is an open-label, randomized, comparative, double-arm, multicenter, phase III study to assess DFS, OS, and safety profiles of the aforementioned drug combination as maintenance therapy for 1year in patients with stage III colon cancer after radical resection in Taiwan. Following the completion of an adjuvant oxaliplatin-based regimen for 3weeks with no evident disease recurrence, all eligible patients will be randomly assigned to either arm A (maintenance therapy) or arm B (observation arm) in a 2:1 ratio (364 and 182 patients in the tegafur-uracil and observation groups, respectively). Treatment in arm A will be started within 7days of randomization. If the patients reported disease recurrence, intolerable toxicity, withdrew consent or the investigator determined that the patient should be withdrawn during the study period, they were withdrawn from the study. If a patient was discontinued from the study, the corresponding data were not reused, and the patient was not allowed to re-enter the study. Discussion: A unique characteristic of this intervention was that the adjuvant chemotherapy with oxaliplatin and tegafur-uracil was anticipated to be safe and has high treatment efficacy, with the advantage of yielding a favorable response rate and tolerable toxicity profile. Trial registration: ClinicalTrials.gov, identifier: NCT02836977. Registered on 18 July 2016.

Original languageEnglish
Article number191
JournalTrials
Volume18
Issue number1
DOIs
Publication statusPublished - Apr 26 2017

Fingerprint

oxaliplatin
Tegafur
Uracil
Colonic Neoplasms
Randomized Controlled Trials
Maintenance
Observation
Drug Combinations
Taiwan
Disease-Free Survival
Recurrence
Survival
Acute Disease
Adjuvant Chemotherapy
Random Allocation

Keywords

  • Oxaliplatin
  • Stage III colon cancer
  • Tegafur-uracil

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Pharmacology (medical)

Cite this

Maintenance tegafur-uracil versus observation following an adjuvant oxaliplatin-based regimen in patients with stage III colon cancer after radical resection : Study protocol for a randomized controlled trial. / Yeh, Yung Sung; Tsai, Hsiang Lin; Huang, Ching Wen; Wei, Po Li; Sung, Yung Chuan; Tang, Hsiu Chih; Wang, Jaw Yuan.

In: Trials, Vol. 18, No. 1, 191, 26.04.2017.

Research output: Contribution to journalArticle

@article{fcf21e1abd40438bafdb83787d24b3d2,
title = "Maintenance tegafur-uracil versus observation following an adjuvant oxaliplatin-based regimen in patients with stage III colon cancer after radical resection: Study protocol for a randomized controlled trial",
abstract = "Background: We conducted a prospective randomized study of an adjuvant oxaliplatin-based regimen plus orally administered tegafur-uracil in patients with stage III colon cancer after radical resection to evaluate the feasibility of this drug combination in cancer clinical outcomes, acute toxicity, disease-free survival (DFS), and overall survival (OS) in Taiwan. Methods/design: This is an open-label, randomized, comparative, double-arm, multicenter, phase III study to assess DFS, OS, and safety profiles of the aforementioned drug combination as maintenance therapy for 1year in patients with stage III colon cancer after radical resection in Taiwan. Following the completion of an adjuvant oxaliplatin-based regimen for 3weeks with no evident disease recurrence, all eligible patients will be randomly assigned to either arm A (maintenance therapy) or arm B (observation arm) in a 2:1 ratio (364 and 182 patients in the tegafur-uracil and observation groups, respectively). Treatment in arm A will be started within 7days of randomization. If the patients reported disease recurrence, intolerable toxicity, withdrew consent or the investigator determined that the patient should be withdrawn during the study period, they were withdrawn from the study. If a patient was discontinued from the study, the corresponding data were not reused, and the patient was not allowed to re-enter the study. Discussion: A unique characteristic of this intervention was that the adjuvant chemotherapy with oxaliplatin and tegafur-uracil was anticipated to be safe and has high treatment efficacy, with the advantage of yielding a favorable response rate and tolerable toxicity profile. Trial registration: ClinicalTrials.gov, identifier: NCT02836977. Registered on 18 July 2016.",
keywords = "Oxaliplatin, Stage III colon cancer, Tegafur-uracil",
author = "Yeh, {Yung Sung} and Tsai, {Hsiang Lin} and Huang, {Ching Wen} and Wei, {Po Li} and Sung, {Yung Chuan} and Tang, {Hsiu Chih} and Wang, {Jaw Yuan}",
year = "2017",
month = "4",
day = "26",
doi = "10.1186/s13063-017-1904-9",
language = "English",
volume = "18",
journal = "Trials",
issn = "1745-6215",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Maintenance tegafur-uracil versus observation following an adjuvant oxaliplatin-based regimen in patients with stage III colon cancer after radical resection

T2 - Study protocol for a randomized controlled trial

AU - Yeh, Yung Sung

AU - Tsai, Hsiang Lin

AU - Huang, Ching Wen

AU - Wei, Po Li

AU - Sung, Yung Chuan

AU - Tang, Hsiu Chih

AU - Wang, Jaw Yuan

PY - 2017/4/26

Y1 - 2017/4/26

N2 - Background: We conducted a prospective randomized study of an adjuvant oxaliplatin-based regimen plus orally administered tegafur-uracil in patients with stage III colon cancer after radical resection to evaluate the feasibility of this drug combination in cancer clinical outcomes, acute toxicity, disease-free survival (DFS), and overall survival (OS) in Taiwan. Methods/design: This is an open-label, randomized, comparative, double-arm, multicenter, phase III study to assess DFS, OS, and safety profiles of the aforementioned drug combination as maintenance therapy for 1year in patients with stage III colon cancer after radical resection in Taiwan. Following the completion of an adjuvant oxaliplatin-based regimen for 3weeks with no evident disease recurrence, all eligible patients will be randomly assigned to either arm A (maintenance therapy) or arm B (observation arm) in a 2:1 ratio (364 and 182 patients in the tegafur-uracil and observation groups, respectively). Treatment in arm A will be started within 7days of randomization. If the patients reported disease recurrence, intolerable toxicity, withdrew consent or the investigator determined that the patient should be withdrawn during the study period, they were withdrawn from the study. If a patient was discontinued from the study, the corresponding data were not reused, and the patient was not allowed to re-enter the study. Discussion: A unique characteristic of this intervention was that the adjuvant chemotherapy with oxaliplatin and tegafur-uracil was anticipated to be safe and has high treatment efficacy, with the advantage of yielding a favorable response rate and tolerable toxicity profile. Trial registration: ClinicalTrials.gov, identifier: NCT02836977. Registered on 18 July 2016.

AB - Background: We conducted a prospective randomized study of an adjuvant oxaliplatin-based regimen plus orally administered tegafur-uracil in patients with stage III colon cancer after radical resection to evaluate the feasibility of this drug combination in cancer clinical outcomes, acute toxicity, disease-free survival (DFS), and overall survival (OS) in Taiwan. Methods/design: This is an open-label, randomized, comparative, double-arm, multicenter, phase III study to assess DFS, OS, and safety profiles of the aforementioned drug combination as maintenance therapy for 1year in patients with stage III colon cancer after radical resection in Taiwan. Following the completion of an adjuvant oxaliplatin-based regimen for 3weeks with no evident disease recurrence, all eligible patients will be randomly assigned to either arm A (maintenance therapy) or arm B (observation arm) in a 2:1 ratio (364 and 182 patients in the tegafur-uracil and observation groups, respectively). Treatment in arm A will be started within 7days of randomization. If the patients reported disease recurrence, intolerable toxicity, withdrew consent or the investigator determined that the patient should be withdrawn during the study period, they were withdrawn from the study. If a patient was discontinued from the study, the corresponding data were not reused, and the patient was not allowed to re-enter the study. Discussion: A unique characteristic of this intervention was that the adjuvant chemotherapy with oxaliplatin and tegafur-uracil was anticipated to be safe and has high treatment efficacy, with the advantage of yielding a favorable response rate and tolerable toxicity profile. Trial registration: ClinicalTrials.gov, identifier: NCT02836977. Registered on 18 July 2016.

KW - Oxaliplatin

KW - Stage III colon cancer

KW - Tegafur-uracil

UR - http://www.scopus.com/inward/record.url?scp=85018661198&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018661198&partnerID=8YFLogxK

U2 - 10.1186/s13063-017-1904-9

DO - 10.1186/s13063-017-1904-9

M3 - Article

C2 - 28441966

AN - SCOPUS:85018661198

VL - 18

JO - Trials

JF - Trials

SN - 1745-6215

IS - 1

M1 - 191

ER -